[Effect of combined treatment of Shuanghuanglian and recombinant interferon alpha 2a on coxsackievirus B3 replication in vitro].
OBJECTIVE
To investigate the effect of combined treatment of Shanghanglian (SHHL) and recombinant interferon alpha 2a on Coxsackie virus B3 replication.


METHODS
Microdose cytopathogenic inhibition effect assay was used in Wish and Vero cultured cells. rIFN-alpha 2a was applied 12 hours before Coxsackievirus B3 inoculation and SHHL was applied 1 hour after Coxsackievirus B3 inoculation.


RESULTS
0.125 mg.ml-1 SHHL has a synergism with rIFN-alpha 2a to inhibit CPE caused by Coxsackievirus B3 on the Wish and Vero cells. The anti-cox-sackievirus activity of combined treatment was 2.58 times higher than that of rIFN-alpha 2a treatment.


CONCLUSIONS
This combined treatment of drugs may be useful in preventing and treating Coxsackie B3 Virus infection.
Lu
H T
HT
Affiliated Children's Hospital of Suzhou Medical College, Suzhou 215003, Jiangsu, China.
Yang
J C
JC
Yuan
Z C
ZC
Sheng
W H
WH
Yan
W H
WH
D000998:Antiviral Agents / Q000494:pharmacology; D004338:Drug Combinations; D004357:Drug Synergism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D029822:Enterovirus B, Human / Q000187:drug effects*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D010946:Plants, Medicinal; D011994:Recombinant Proteins; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins